Azenta (AZTA) Stock Forecast & Price Target

Azenta is attractive because F4Q26 showed clear operating momentum, with revenue of $167M, adjusted EBITDA of $19M, and adjusted EPS of $0.28 all beating consensus, while margins improved as adjusted gross margin reached 47.2% and operating margin rose to 6.9%. The company’s core Sample Management Solutions business remained a growth engine, as SRS and C&I accelerated in the quarter, and FY27 guidance of $648M-$660M revenue plus 200-250 bps of adjusted EBITDA margin expansion came in ahead of consensus, signaling stronger profitability ahead. Multiomics also supports the thesis, with North America stable sequentially and recent restructuring plus Elegen and SynPlexity investments positioned to improve scalability and drive better growth as commercialization ramps.

Azenta is facing a weak fundamental setup as the bear case assumes flat-to-down revenue growth, which could drive margin contraction and flat or negative earnings growth across its sample management and multiomics businesses. Management already lowered FY26 adjusted EBITDA guidance to $56-59M from $59-62M due to a one-time $3M consulting expense, while estimates were cut to $56M from $59M and adjusted EPS to $0.33 from $39. The outlook remains pressured by macro headwinds, continued market weakness, and the risk that revenue- or margin-dilutive M&A could further erode profitability even as FY27 sales were raised to $650M and FY28 to $680M.